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Summary
Although hemophilia has a potentially high economic impact, published estimates of health care 
costs for Americans with hemophilia are sparse and non-specific as to the non-bleeding 
complications of the disease. The objective of this study is to estimate average annual health care 
expenditures for people with hemophilia covered by employer-sponsored insurance, stratified 
according to the influence of age, type of hemophilia [A (factor VIII deficiency) versus B (factor 
IX)], presence of neutralizing alloantibody inhibitors and exposure to blood-borne viral infections. 
Data from the Market-Scan® Commercial and Medicare Research Databases were used for the 
period 2002–2008 to identify cases of hemophilia and to estimate mean and median medical 
expenditures during 2008. A total of 1,164 males with hemophilia were identified with continuous 
enrollment during 2008, 933 with hemophilia A and 231 with hemophilia B. Mean health care 
expenditures were $155,136 [median $73,548]. Mean costs for 30 (3%) males with an inhibitor 
were 5 times higher than for males without an inhibitor, approximately $697,000 [median 
$330,835] and $144,000 [median $73,321], respectively. Clotting factor concentrate accounted for 
70%–82% of total costs. Average costs for 207 adults with HCV or HIV infection were 1.5 times 
higher than those for adults without infection. Hemophilia treatment is costly, particularly for 
individuals with neutralizing alloantibody inhibitors who require bypassing agents. Efforts to 
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understand the cause of inhibitors are needed so that prevention strategies can be implemented and 
the excess costs resulting from this serious complication of hemophilia care can be avoided.
Keywords
claims data; cost of care; employer-sponsored insurance; haemophilia; inhibitor; MarketScan 
Commercial and Medicare databases
Introduction
Haemophilia is a rare bleeding disorder, affecting approximately 1 in 5000–10 000 live-born 
males, that can require regular treatment with clotting factor concentrate [1–3]. Bleeding 
typically occurs into soft tissues and joints, with repeated haemorrhage leading to pain, 
deformity and disability [1,4]. Despite the relatively small number of affected individuals, 
an estimated 20 000 individuals in the United States, haemophilia has a large impact on 
individuals, healthcare systems, and society [5,6].
Published estimates suggest that average (mean) healthcare costs for Americans with 
haemophilia are approximately $100,000 to $150,000 per year [7]. Inhibitors are antibodies 
that render the treatment products ineffective in controlling bleeding and have been reported 
to occur in 10–15% of people with haemophilia. Approximately 4% of haemophilia patients 
receive bypassing agents to manage haemophilia [8]. Previous studies have found that the 
mean healthcare costs of treating people with bypassing agents for inhibitors can be 2–3 
times higher than those of people without inhibitors [9–11,12 excluding outliers]. In 
addition, one study found that the presence of HIV or HCV infection resulted in 59% greater 
healthcare costs compared with costs for haemophilia alone among adults [8].
Previous estimates of haemophilia costs were based on relatively small numbers of patients, 
which may lead to biased estimates of cost since a small sample is less likely to be 
representative of the whole population. The purpose of this study was to estimate average 
annual costs of health care for people with haemophilia enrolled in employer-sponsored 
insurance by age, type of haemophilia, inhibitor status, and viral infection status using US 
health insurance claims data.
Methods
Data
The data for this study were obtained from the MarketScan® Commercial and Medicare 
Supplemental and COB databases (Thomson Reuters Inc., New York, NY, USA) for the 
period 2002–2008. Between them, the databases provided data on approximately 37 million 
active employees, early retirees, COBRA participants (Commercial database), and 
Medicare-eligible retirees (Medicare database) and their dependents in 2008. Both groups 
are insured by employer-sponsored plans.
The databases comprised four sources: outpatient drug claims, outpatient service claims, 
inpatient service claims and inpatient admission claims. The data use three types of medical 
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codes: (i) International Classification of Disease, Ninth Revision, Clinical Modification 
(ICD-9-CM); (ii) healthcare common procedure coding system (HCPCS); and (iii) National 
Drug Code (NDC). Demographic information on gender, age and annual enrolment, as well 
as information on medical costs is provided for all insurance enrollees who are assigned a 
unique identification code that allows tracking of individuals over time.
Sample selection criteria
Figure 1 presents the process used to identify people with haemophilia. People with 
haemophilia were identified if they met three criteria: (i) had an insurance claim during the 
years 2002–2008 with an ICD-9 code for haemophilia (286.0 or 286.1); (ii) were male; and 
(iii) had records between 2002 and 2008 with either anti-haemophilia drug claims or 
haemophilia-specific procedure codes (see Table S1 of Appendix). The criteria were 
developed to minimize coding errors. For example, many females had haemophilia ICD-9 
codes. As true haemophilia is rare in females, it is likely that most females coded in this way 
in the database were either carriers of the haemophilia gene or had another coagulation 
disorder, but were miscoded.
Prevalence based on claims data was calculated by dividing the number of males with 
haemophilia by the number of males in employer-sponsored plans, including Medicare 
Supplemental plans paid by employers. For the purpose of estimating expenditures, the 
sample was further restricted to individuals with at least 11 months of coverage during 2008 
because inclusion of enrollees with partial-year coverage and annual medical expenditures 
could lead to underestimates of annual costs.
People who were treated for inhibitors to factor VIII with certain anti-haemophilia products 
referred to as bypassing agents were identified using outpatient visit claims, outpatient drug 
claims (for home infusion), or inpatient procedure codes for infusion with bypassing agents. 
As we were not able to identify people with an inhibitor who did not receive these bypassing 
drugs, the study sample represents a subset of people with an inhibitor.
Adults with haemophilia were determined to be HIV-or HCV-infected based on either 
diagnosis or specifically anti-HIV or anti-HCV medicine drug codes (Table S1 of 
Appendix).
Finally, we established six risk groups according to age, type of haemophilia, treatment of 
an inhibitor with bypassing agents (hereafter referred to as individuals with inhibitors) and 
infection with HIV or HCV. They are: (i) children (age <18 years) with haemophilia A and 
inhibitors; (ii) children with haemophilia A without inhibitors; (iii) children with 
haemophilia B; (iv) adults with haemophilia A or haemophilia B with inhibitors; (v) adults 
with blood-borne viral infection without inhibitors; and (vi) adults without viral infection or 
inhibitors (Fig. 1). The few adults with both viral infection and inhibitors were included in 
the inhibitor group for the analyses.
Outcome measures
The cost of health care was defined as the sum of expenditures by insurers and individuals 
during 2008. Average costs were calculated for six risk groups in terms of both the mean 
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(total expenditures within the group divided by total number of individuals) and the median 
(annual expenditure for the median individual). Significance tests are reported for group 
differences in mean and expenditures, but not for medians. Mean expenditures have 
desirable statistical properties, including the ability to aggregate by component and across 
individuals in the sample.
Clotting factor procedure claims from the inpatient and outpatient files were combined with 
outpatient drug claims to calculate total clotting factor expenditures. The inpatient claims 
data in particular do not provide a full breakdown of costs for each procedure code. 
Therefore, factor costs include the cost of inpatient administration. They also included costs 
for both factor concentrates and bypassing agents.
Results
All persons with haemophilia
Of the 18 million males covered in 2008, a total of 1420 persons met our criteria and were 
identified as having haemophilia (Table 1). The prevalence of haemophilia based on the 
claims data was 0.79 per 10 000 insured males. Age-specific prevalence was highest for 
males aged 10–19 years, after which the prevalence decreased with age. Overall, the 
prevalence for children (<age 18; 1.42 per 10 000 males) was significantly higher than that 
of adults (≥ age 18; 0.57 per 10 000 males, P < 0.01).
A total of 1164 (82% of 1420) males with haemophilia were enrolled for at least 11 months 
in 2008 (Table 2). Of the 1164 males with haemophilia, 80% (n = 933) had haemophilia A 
and 20% (n = 231) had haemophilia B. A total of 30 males (3%) were identified as having 
an inhibitor to factor VIII based on their use of bypassing agents. One-third of people with 
haemophilia had at least one emergency department (ED) visit and 14% had an inpatient 
admission. Among those with at least one ED visit or admission, the mean numbers of ED 
visits and admissions were 2.8 and 1.4, respectively.
Table 2 also shows that annual costs for all males with haemophilia averaged $155,136 
[median $73,548] in 2008. Mean healthcare costs were higher for individuals with 
haemophilia A ($162,054 [median $78,598]) than those with haemophilia B ($127,194 
[median $55,220], P = 0.06).
Among people with haemophilia A, average annual total costs for people with an inhibitor 
were 4.8 times higher than total costs for non-inhibitor patients ($696,279 [median 
$330,835] vs. $144,306 [median $73,321]; P < 0.01). Similarly, the average annual cost for 
clotting factor was 4.6 times higher among people with an inhibitor ($573,760 [median 
$299,651] vs. $123,154 [median $51,869], P < 0.01). Clotting factor (including factor 
concentrates and bypassing agents) accounted for roughly the same proportion of total costs 
regardless of whether or not an inhibitor was present, 82% and 85%, respectively.
Although annual costs were similar for children and adults overall ($150,680 [median 
$72,374] vs. $159,310 [median $76,088], respectively, P = 0.56), the amounts varied by 10-
year age group (P < 0.05; Table S2 of Appendix).
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Children with haemophilia
Among 563 children, 466 (83%) had haemophilia A and 14 (3%) of them were treated with 
a bypassing agent for an inhibitor during 2008 (Table 3). Children with haemophilia A and 
an inhibitor were on average 3 years younger than those without an inhibitor (P = 0.02). All 
children with inhibitors received clotting factor compared with 85% of those without an 
inhibitor. Furthermore, compared with children without an inhibitor, a higher proportion of 
children with an inhibitor had an ED visit in 2008, (71% vs. 36%, P < 0.01). Also, among 
those with at least one ED visit, the mean number of visits was greater among children with 
an inhibitor. Similarly, a higher proportion of children with an inhibitor had inpatient 
admissions (43% vs. 10%, P < 0.01).
The average annual cost for children with haemophilia A and an inhibitor was $831,866 
[median $461,527] in 2008, which was six times higher than that for children with 
haemophilia A without an inhibitor ($142,057 [median $73,659], P < 0.01).
Among children without an inhibitor, there was no difference in average age between 
children with haemophilia A and haemophilia B. Compared with children with haemophilia 
B, a higher proportion of children with haemophilia A received factor during 2008 (85% vs. 
64%, P < 0.01) and mean and median costs were 1.5 and 2.0 times higher ($142,057 
[median $73,659] vs. $92,546 [median $36,177], P < 0.001). Conversely, a higher 
proportion of children with haemophilia B had at least one ED visit (49% vs. 36%, P < 
0.05).
Adults with haemophilia
As shown in Table 4, of 601 adults with haemophilia, 207 (34%) were infected with HIV or 
HCV, 16 (3%) of whom also had an inhibitor. Adults with an inhibitor were more likely to 
use clotting factor (100% vs. 74%, P < 0.01), more likely to visit the ED (63% vs. 28%, P < 
0.01) and more likely to require inpatient services (31% vs. 12%, P < 0.05) than those 
without an inhibitor.
Adults with HIV or HCV infection were on average 5 years older than those uninfected (P < 
0.01). Compared with those without infection, a higher proportion of infected adults 
received clotting factor in 2008, (91% vs. 74%, P < 0.01) and had an inpatient admission 
(22% vs. 12%, P < 0.01). There was no significant difference in the proportion of adults 
who visited EDs by blood-borne viral infection status.
The mean annual cost for adults with an inhibitor ($577,640 [median $176,218]) was 3–5 
times higher than the costs for adults either with ($188,056 [median $116,207], P < 0.01) or 
without ($125,861 [median $43,968], P < 0.01) HIV or HCV infection. The average annual 
costs were $188,056 for infected adults, which was 1.5 times higher than cost for adults 
without infection ($125,861, P < 0.01).
The cost for clotting factors was 1.4 times ($151,634 [median $95,600]) for adults with HIV 
or HCV infection higher than the costs for adults without the infection ($107,985 [median 
$27,561], P < 0.01). Among adults with HIV or HCV infection, clotting factors accounted 
for 81% of total costs, while the cost of antiviral treatment accounted for 7% ($13,501). 
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There is no statistically significant difference in total costs or costs for clotting factors 
among three different blood-borne viral infection groups (HIV only, HCV only, and co-
infection group; see Fig. S1 of Appendix).
Discussion
This is the second published study to use US health insurance claims data to identify insured 
persons with haemophilia and to investigate their use of health services and associated 
expenditures. Compared with the first study, which identified just 173 adults with 
haemophilia from approximately 21 million males enrolled in commercial health plans [8], 
we identified 601 adult males with haemophilia from among 9.7 million adult males 
enrolled in employer-sponsored health insurance plans. Tencer et al. [8] restricted their 
analysis to individuals who had at least one primary diagnosis of haemophilia or other 
bleeding disorder (ICD-9 286.xx) and at least one prescription for a haemophilia drug. Our 
criteria included ICD-9 codes specific to haemophilia (286.0–286.1), regardless of whether 
it was a primary diagnosis, and we did not require a prescription claim for a haemophilia 
drug. Based on prevalence estimates, our sample appears to be fairly representative of 
privately insured males with haemophilia.
We found that the annual healthcare cost in 2008 averaged $155,136 [median $73,548] 
($150,680 [median $72,374] for children and $159,310 [median $76,088] for adults). 
Healthcare costs were particularly elevated for people who were treated with bypassing 
agents for inhibitors, 4–6 times higher on average, depending on age group. Our estimates 
are consistent with one set of results from one study [12 including outliers], but the cost ratio 
appears high relative to the results of other studies, all of which reported that annual costs 
for inhibitor patients were 2–3 times higher than those without inhibitors [9–11,12 excluding 
outliers, 13]. However, other studies for the most part were not restricted to inhibitor 
patients receiving bypassing agents and were not based on US data.
In our data, the average cost differed by 10-year age group, tending to increase with age 
until the age of 49 and then to decrease. Two possible explanations for why people with 
haemophilia who remained on employer-sponsored insurance incurred lower costs after age 
49 are (i) that as people aged, they became less physically active and hence had fewer bleeds 
and (ii) older people were more likely to use plasma products, which are less expensive than 
recombinant products. However, another reason for the decrease in costs after age 49 in our 
data could be that people with haemophilia who had higher health-care spending left 
employer- sponsored insurance and moved to public insurance. There are several possible 
explanations for such a shift: (i) insurance caps that cause older people to reach the lifetime 
maximum on their health insurance; (ii) the exclusion of haemophilia as a pre-existing 
condition from health insurance coverage when people change employment (both employees 
and dependents); (iii) selective mortality; and (iv) the healthy worker effect (healthier 
people, including people with mild symptoms, are more likely to be employed and therefore 
remain in employer-sponsored plans). The healthy worker effect is not statistically 
supported as an explanation in this case as average costs were the same regardless of 
employment status (see Table S3 of Appendix).
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The decreased prevalence of haemophilia among adults also reflects the high mortality 
among adults with haemophilia who developed HIV or other viral infections in the 1980s. 
Children in this study sample, born after 1990, have been largely unexposed to viral 
infection owing to the introduction of high-purity viral inactivated plasma-derived factor 
concentrates in the late 1980s and the development of recombinant products in the early 
1990s [14]. The greater decrease in prevalence with age relative to a population-based study 
of haemophilia prevalence [3] reflects factors described in the previous paragraph, which 
reduce the likelihood that adults with haemophilia will continue to have employer-sponsored 
health insurance.
Mean expenditures for privately insured adults infected with HIV or HCV were 1.5 times 
higher than those for adults without blood-borne viral infection. The additional costs due to 
blood-borne viral infection were mostly attributable to higher use of factor concentrate. 
Factor concentrate accounted for ≥ 79% of total costs for these adults with blood-borne 
infection, which means that antiviral treatment for blood-borne infections does not account 
for their higher healthcare costs. They use more factor concentrate and therefore cost more.
The limitations of this study include, first, that the study sample is not representative of the 
haemophilia population as only people who were covered by employer-sponsored plans or 
Medicare Supplemental plans were included in the study. Second, because we required that 
people must have either haemophilia-related procedure or drug codes, people with mild 
symptoms who did not receive haemophilia-specific treatment were excluded. Therefore, 
our estimates of average cost apply only to people treated for haemophilia. To the extent that 
people with mild symptoms are under-represented in our database, our estimates would 
overstate average costs for the population with haemophilia as a whole. Third, a limitation 
of the analysis of costs associated with comorbidity from blood-borne viral infections is that 
we were only able to identify people who received antiviral treatments, and many HCV-
infected people do not actively receive anti-HCV treatment. Fourth, costs may be 
understated because people may receive factor concentrate from a source other than their 
private plan or Medicare Supplemental plan, and these costs of care were not included in the 
analysis. Fifth, information on laboratory tests for inhibitors or inhibitor status was not 
available, and our estimated costs for people who received bypassing agents cannot be 
extrapolated to people with an inhibitor in general. In particular, people with an inhibitor 
may instead be treated with large amounts of factor VIII or factor IX to overcome the 
inhibitor (immune tolerance therapy) and may have been included in the group not on 
bypassing agents (but on immune tolerance); therefore, the excess cost of inhibitor patients 
may have been underestimated.
In conclusion, we found that people with haemophilia incur substantial healthcare costs 
primarily due to the use of factor concentrates to control bleeding. These costs can be 
dramatically increased by the development of an inhibitor and for some adults with HCV or 
HIV infection. Although these costs are high, the costs resulting from severe complications 
that occur without appropriate use of factor concentrates could be far greater. Efforts to 
understand the cause of inhibitors are needed so that prevention strategies can be 
implemented and the excess costs resulting from this serious complication of haemophilia 
care can be avoided.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Flowchart of sample selection.
Note: C = child; HA = haemophilia A; HB = haemophilia B; B+ = treatment for an inhibitor 
with bypassing agents; B− = no treatment for an inhibitor with bypassing agents; A = adult; 
H = haemophilia; V+ = with blood-borne viral infection; V− = without blood-borne viral 
infection. † About 17.9 million males were enrolled in private health plans and Medicare, on 
average, for 10 months in 2008.
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Table 2
Annual costs of care of males with haemophilia by risk group, 2008.
N Median Mean 95th percentile
Healthcare utilization
 No. of admission w ≥ 1 admission 164 (14%) 1.0 1.4 4.0
 No. of ED visits w ≥ 1 visit 379 (33%) 1.0 2.8 9.0
Healthcare expenditures
 All 1164 73 548 155 136 560 238
 Haemophilia A‡ 933 78 598 162 054† 578 958
 Haemophilia B‡ 231 55 220 127 194 489 101
 Receiving no bypassing agents§ 903 73 321 144 306†** 527 944
  Clotting factor¶ 903 51 869 123 154†** 489 084
 Receiving bypassing agents§ 30 330 835 696 279 2 459 207
  Clotting factor¶ 30 299 651 573 760 2 434 958
 Child†† 563 72 374 150 680† 529 024
 Adult†† 601 76 088 159 310 613 315
**
represents a 1% level of significance.
†
t test.
‡Statistical tests examine the null hypothesis that people with haemophilia A have the same costs of care as people with haemophilia B.
§Statistical tests examine the null hypothesis that people who receive bypassing agents have the same costs of care as people who do not receive 
bypassing agents.
¶Statistical tests examine the null hypothesis that the costs of clotting factor for people who receive bypassing agents are the same as those for 
people who do not receive bypassing agents.
††Statistical tests examine the null hypothesis that children have the same costs of care as adults.
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Table 3
Characteristics of children with haemophilia by risk group, 2008.
Children
Haemophilia A
Haemophilia B (CHB) ††
Receiving no bypassing agents 
(CHAB−)R
Receiving bypassing agents 
(CHAB+)¶
No. of people 452 14 97
Age group: N (%) P = 0.20§ P = 0.21†
 0–4 87 (19) 6 (43) 17 (18)
 5–9 112 (25) 3 (21) 22 (23)
 10–14 170 (38) 3 (21) 32 (33)
 15–17 83 (18) 2 (14) 26 (27)
 Age (mean) 10 7*† 10†
Clotting factor
 No. of people (%) 386 (85) 14 (100)§ 62 (64)**‡
Emergency department (ED) visits
 No. of people (%) 163 (36) 10 (71)**‡ 48 (49)*‡
 Frequency among ED visitors 2.3 5.7**† 2.1†
Type of care: N (% of people who received each type of care)
 Inpatient 44 (10) 6 (43)**‡ 16 (16)‡
 Prescription 164 (36) 0 (0)**§ 26 (27) ‡
Total expenditures ($)
 Median 73 659 461 527 36 177
 Mean 142 057 831 866**† 92 546**†
 95th percentile 527 944 4 674 076 339 790
Expenditures for clotting factor ($)
 Median 53 287 375 384 18 996
 Mean 124 752 728 737**† 77 610**†
 95th percentile 489 393 4 141 157 338 048
* and **
represent a 5% and a 1% level of significance, respectively.
†
t test.
‡Chi-square test.
§
Fisher’s exact test.
¶Statistical tests examine the null hypothesis that the CHAB− group has the same characteristics as the CHAB+ group.
††Statistical tests examine the null hypothesis that the CHAB− group has the same characteristics as the CHB group.
R
Reference.
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Table 4
Characteristics of adults with haemophilia by risk group, 2008.
Adults
Receiving no bypassing agents
Receiving bypassing agents 
(AHB+)††
w/o HIV or HCV infection 
(AHV−)R
w HIV or HCV infection (AHV+)
¶
No. of people 378 207 16
HIV only – 48 –
HCV only – 94 –
HIV and HCV – 65 –
Age group: N (%) P < 0.01‡ P = 0.02§
 18–29 187 (49) 31 (15) 2 (13)
 30–39 42 (11) 58 (28) 3 (19)
 40–49 52 (14) 70 (34) 4 (25)
 50–59 48 (13) 43 (21) 3 (19)
 60–69 33 (9) 4 (2) 2 (13)
 70–79 8 (2) – 1 (6)
 80– 8 (2) 1 (0.5) 1 (6)
 Age (mean) 37 42**† 48*†
Clotting factor
 No. of people (%) 281 (74) 188 (91)**‡ 16 (100)**§
Emergency department (ED) visits
 No. of people (%) 107 (28) 64 (31)‡ 10 (63)**‡
 Frequency among ED visitors 1.7 2.0† 2.3†
Type of care: N (% of people who received each type of care)
 Inpatient 47 (12) 46 (22)**‡ 5 (31)*‡
 Prescription 121 (32) 64 (31)‡ 5 (31)‡
Total expenditures ($)
 Median 43 968 116 207 176 218
 Mean 125 861 188 056**† 577 640**†
 95th percentile 520 976 620 918 2 459 207
Expenditures for clotting factor ($)
 Median 27 561 95 600 111 147
 Mean 107 985 151 634**† 438 155**†
 95th percentile 440 717 542 318 2 434 958
* and **
represent a 5% and a 1% level of significance, respectively.
†
t test.
‡Chi-square test.
§
Fisher’s exact test.
¶Statistical tests examine the null hypothesis that the AHV− group has the same characteristics as the AHV+ group.
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††Statistical tests examine the null hypothesis that the AHB+ group has the same characteristics as the AHV− group.
R
Reference.
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